Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Lipid parameters and cardiovascular events in patients taking statins.

Martin SS, Jones SR.

JAMA. 2012 Jul 11;308(2):131-2; author reply 132-3. doi: 10.1001/jama.2012.6614. No abstract available.

PMID:
22782402
2.

Lipid parameters and cardiovascular events in patients taking statins.

Brook RD, Rubenfire M.

JAMA. 2012 Jul 11;308(2):132; author reply 132-3. doi: 10.1001/jama.2012.6616. No abstract available.

PMID:
22782403
3.

Among statin-treated patients, LDL, non-HDL and apoB cholesterol biomarkers were associated with increased risks of cardiovascular events.

Sniderman AD, Thanassoulis G.

Evid Based Med. 2013 Apr;18(2):73-4. doi: 10.1136/eb-2012-100787. Epub 2012 Aug 14. No abstract available.

PMID:
22893654
4.

Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.

Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes RJ, Durrington P, Hitman GA, Welch KM, DeMicco DA, Zwinderman AH, Clearfield MB, Downs JR, Tonkin AM, Colhoun HM, Gotto AM Jr, Ridker PM, Kastelein JJ.

JAMA. 2012 Mar 28;307(12):1302-9. doi: 10.1001/jama.2012.366. Erratum in: JAMA. 2012 May 9;307(18):1915. JAMA. 2012 Apr 25;307(16):1694.

PMID:
22453571
5.

Zetia (ezetimibe).

Kloner RA.

Congest Heart Fail. 2003 Mar-Apr;9(2):109-10. No abstract available.

6.

PCSK9 Inhibitors and Cardiovascular Events.

Sabatine MS, Wasserman SM, Stein EA.

N Engl J Med. 2015 Aug 20;373(8):774-5. No abstract available.

PMID:
26295078
7.

PCSK9 Inhibitors and Cardiovascular Events.

Goemann IM, Londero TM, Dora JM.

N Engl J Med. 2015 Aug 20;373(8):773-4. doi: 10.1056/NEJMc1508222#SA2. No abstract available.

PMID:
26287856
8.

Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment.

Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, Walldius G.

Lancet. 2003 Mar 1;361(9359):777-80. No abstract available.

PMID:
12620753
9.

PCSK9 inhibitors reduce cardiovascular events, preliminary data show.

Mayor S.

BMJ. 2015 Mar 17;350:h1508. doi: 10.1136/bmj.h1508. No abstract available.

PMID:
25782694
10.

Lowering LDL cholesterol is good, but how and in whom?

Stone NJ, Lloyd-Jones DM.

N Engl J Med. 2015 Apr 16;372(16):1564-5. doi: 10.1056/NEJMe1502192. Epub 2015 Mar 15. No abstract available.

PMID:
25773740
11.

Efficacy and safety of treatment with low-dose fluvastatin in hypercholesterolemic renal transplant recipients.

Akiyama T, Ishii T, Imanishi M, Nishioka T, Matsuura T, Kurita T.

Transplant Proc. 2001 May;33(3):2115-8. No abstract available.

PMID:
11377469
12.

[Statins remain the standard. New methods for lipid lowering therapy].

Aumiller J.

MMW Fortschr Med. 2001 Oct 18;143(42):16-7. German. No abstract available.

PMID:
11697281
13.

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.

Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC; Treating to New Targets Investigators..

N Engl J Med. 2007 Sep 27;357(13):1301-10.

14.

[When statins alone are not enough. Putting a vice grip on cholesterol].

[No authors listed]

MMW Fortschr Med. 2002 Jun 6;144(23):52-3. German. No abstract available.

PMID:
12119909
15.

PCSK9 Inhibitors and Cardiovascular Events.

Auer J, Berent R, Primus C.

N Engl J Med. 2015 Aug 20;373(8):773. doi: 10.1056/NEJMc1508222#SA1. No abstract available.

PMID:
26287855
16.

PCSK9 Inhibitors and Cardiovascular Events.

Robinson JG, Kastelein JJ.

N Engl J Med. 2015 Aug 20;373(8):774. doi: 10.1056/NEJMc1508222. No abstract available.

17.

A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.

Alla VM, Agrawal V, DeNazareth A, Mohiuddin S, Ravilla S, Rendell M.

Drugs. 2013 Jul;73(10):1025-54. doi: 10.1007/s40265-013-0072-9. Review.

PMID:
23754124
18.

[Hyperlipidemia: decreasing lipid values and effects of statins].

Mathes P.

Z Kardiol. 2002;91 Suppl 2:25-9. Review. German. No abstract available.

PMID:
12436762
19.

Dyslipidaemia. Assessing the efficacy and safety of evolocumab and alirocumab.

Huynh K.

Nat Rev Cardiol. 2015 May;12(5):261. doi: 10.1038/nrcardio.2015.51. Epub 2015 Mar 31. No abstract available.

PMID:
25824512
20.

Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.

Broyles FE, Walden CE, Hunninghake DB, Hill-Williams D, Knopp RH.

Am J Cardiol. 1995 Jul 13;76(2):129A-135A.

PMID:
7604788

Supplemental Content

Support Center